Saikosaponin D inhibits gastric cancer progression by targeting PKM2-mediated glycolysis and histone lactylation - PubMed
3 hours ago
- #Glycolysis
- #Gastric Cancer
- #Histone Lactylation
- Saikosaponin D (SSD) inhibits gastric cancer (GC) progression by targeting PKM2-mediated glycolysis and histone lactylation.
- SSD reduces viability, proliferation, migration, and invasion of GC cells (BGC-823 and SGC-7901) in a dose-dependent manner.
- SSD promotes apoptosis in GC cells by upregulating cleaved caspase-3/9 expression.
- In vivo, SSD inhibits xenograft tumor growth and decreases Ki-67 expression and pan-lactylation.
- SSD downregulates PKM2 expression, suppressing glycolysis-related metabolic processes and reducing pan-lactylation and H3 histone lactylation levels.
- PKM2 overexpression reverses SSD-induced inhibition of GC cell proliferation and reduction in H3 histone lactylation.
- SSD's anti-tumor mechanism involves suppression of PKM2-mediated glycolysis and regulation of protein and histone lactylation.